Sparks commentary - Mendus

Healthcare

Sparks - Mendus

More on this equity
Mendus (OMX: IMMU) presents DCOne platform update
Published by Arron Aatkar, PhD

On 3 April 2025, Mendus has announced that the company presented data from its proprietary DCOne platform at the Immunotherapy of Cancer Conference. The presentation showcased the potential of the platform to expand ovarian cancer tumour-infiltrating lymphocytes (TIL), and overcome key hurdles in the production of TIL-based therapies for solid tumours. For further details, we refer readers to the press release.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free